Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia

NCT05576532 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

T-lymphoblastic Lymphoma
Relapsed Disease
Refractory Lymphoma
Refractory Leukemia
Safety
Efficacy, Self

Interventions

DRUG: BCL2 Inhibitor plus IM2 regimen

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine